Prelude Therapeutics
PRLD
48 hedge funds and large institutions have $82.6M invested in Prelude Therapeutics in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 9 closing their positions.
111% more capital invested
Capital invested by funds: $39.1M → $82.6M (+$43.5M)
17.07% more ownership
Funds ownership: 47.99% → 65.06% (+17%)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 47 → 48 (+1)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
80% less call options, than puts
Call options by funds: $19K | Put options by funds: $97K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.33M |
| 2 |
Two Sigma Investments
New York
|
+$1.07M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$711K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$462K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.68M |
| 2 |
Renaissance Technologies
New York
|
-$460K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$203K |
| 4 |
SC
Shay Capital
New York
|
-$144K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$108K |
PRLD Hedge Fund Activity: Q4 2025 in Review
48 of the 8,277 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2025, worth a combined $82.6M — up 111% from $39.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PRLD positions and 9 closed out — a net gain of 1 holder — while 14 added to existing stakes and 15 trimmed.
The largest buyer was Kynam Capital Management, opening a new position worth an estimated $1.33M. The largest seller was Millennium Management, cutting an estimated $1.68M.
- 48 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2025, up from 47 in Q3 2025.
- Funds reported $82.6M of Prelude Therapeutics stock for Q4 2025, up 111% quarter-over-quarter.
- 10 funds opened new Prelude Therapeutics positions in Q4 2025 and 9 closed out, a net change of +1 holder.
- The largest Prelude Therapeutics buyer in Q4 2025 was Kynam Capital Management, an estimated $1.33M added.
- The largest Prelude Therapeutics seller in Q4 2025 was Millennium Management, an estimated $1.68M sold.
Based on aggregated 13F filings for Q4 2025.